Liver stiffness: a novel imaging biomarker by ultrasound elastography for prediction of early allograft failure following liver transplantation.

Abstract

Objectives: The objective of this study was to evaluate the role of Liver Stiffness Measurement (LSM) and serum transaminase levels for predicting early allograft failure (EAF) after liver transplantation (LT).

Methods: A total of 189 patients who underwent LT were prospectively recruited in the study. Of these patients, 13 cases died or received re-transplantation within 90 days after surgery were classified as EAF group, while rest 176 patients were included in the non-EAF group. LSM values and serum transaminase levels within 1 week after operation were recorded and compared between two groups. The area under the curve (AUC) was utilized to assess the performance of LSM, serum transaminase and their combination in predicting EAF.

Results: The earliest significant difference in LSM between EAF and non-EAF group was observed on postoperative day 3 (POD-3) (p = 0.046). Comparing to non-EAF group, patients in the EAF group had higher aspartate-aminotransferase (AST) and alanine aminotransferase (ALT) on postoperative day 2 (POD-2)(p = 0.009, 0.033), and also demonstrated higher AST on POD-3 (p = 0.021). Furthermore, the reduction rate of AST/ALT from day 1 to day 3 (AST/ALT Red) were slower (p = 0.001, 0.014) in EAF group. Using a LSM value > 12.1 kPa and an AST level > 339U/L on POD-3 predicted EAF with a sensitivity of 89%, a specificity of 86%, and an AUC of 0.926, surpassing the traditional early allograft dysfunction (EAD) model.

Conclusions: The combination of LSM values and AST levels on the third day after LT can effectively predict EAF and facilitate timely interventions.